A small, light-activated molecule recently tested in mice represents a new approach to eliminating clumps of amyloid protein found in the brains of Alzheimer’s disease patients. If perfected in humans, the technique could be used as an alternative approach to immunotherapy and used to treat other diseases caused by similar amyloids.
Researchers injected the molecule directly into the brains of live mice with Alzheimer’s disease and then used a specialized probe to shine light into their brains for 30 minutes each day for one week. Chemical analysis of the mouse brain tissue showed that the treatment significantly reduced amyloid protein. Results from additional experiments using human brain samples donated by Alzheimer’s disease patients supported the possibility of future use in humans.
“The importance of our study is developing this technique to target the amyloid protein to enhance clearance of it by the immune system,” said Yukiko Hori, a lecturer at the University of Tokyo and co-first author of the research recently published in Brain.
The small molecule that the research team developed is known as a photo-oxygenation catalyst. It appears to treat Alzheimer’s disease via a two-step process.
First, the catalyst destabilizes the amyloid plaques. Oxygenation, or adding oxygen atoms, can make a molecule unstable by changing the chemical bonds holding it together. Laundry detergents or other cleaners known as “oxygen bleach” use a similar chemical principle.
The catalyst is designed to target the folded structure of amyloid and likely works by cross-linking specific portions called histidine residues. The catalyst is inert until it is activated with near-infrared light, so in the future, researchers imagine that the catalyst could be delivered throughout the body by injection into the bloodstream and targeted to specific areas using light.
Second, the destabilized amyloid is then removed by microglia, immune cells of the brain that clear away damaged cells and debris outside healthy cells. Using mouse cells growing in a dish, researchers observed microglia engulfing oxygenated amyloid and then breaking it down in acidic compartments inside the cells.
“Our catalyst binds to the amyloid-specific structure, not to a unique genetic or amino acid sequence, so this same catalyst can be applied to other amyloid depositions,” said Professor Taisuke Tomita, who led the project at the University of Tokyo.
The American Society of Clinical Oncology estimates that each year in the U.S., 4,000 people are diagnosed with diseases caused by amyloid outside of the brain, collectively known as amyloidosis.
The photo-oxygenation catalyst should be capable of removing amyloid protein, regardless of when or where it formed in the body. Although some existing Alzheimer’s disease treatments can slow the formation of new amyloid plaques, eliminating existing plaques is especially important in Alzheimer’s disease because amyloid begins aggregating years before symptoms appear.
The research team is now working to modify the design of the catalyst so it can be activated by shining light through the skull.
More from: University of Tokyo
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Reducing amyloid protein
- FDA Drug Approvals — 2021 Midyear Reviewon August 20, 2021 at 3:05 pm
ANGPTL3 inhibits lipoprotein lipase and endothelial lipase, thereby reducing lipid metabolism ... received casimersen showed a significantly greater increase in dystrophin protein levels from baseline ...
- Genome-Editing Strategy Developed For Potential Alzheimer’s Disease Therapy: Studyon August 19, 2021 at 9:01 am
An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a novel ...
- Scientists identify the main components driving amyloid beta-associated synapse degenerationon August 18, 2021 at 6:34 pm
Healthy adult brains are endowed with a vast number of synapses, structures that relay signals across nerve cells to enable communications, information processing and storage throughout the nervous ...
- Key mechanisms behind synapse degeneration in Alzheimer’s brain discoveredon August 18, 2021 at 5:54 pm
Neurobiologists have uncovered the long-sought-after mechanisms behind the maintenance and decline of key synapses implicated in brain disorders such as Alzheimer's disease. The researchers identified ...
- NeuroScientific Biomarpharmaceuticals (NSB) shares rise on COVID-19 test resultson August 18, 2021 at 3:00 pm
NeuroScientific Biopharmaceuticals (ASX:NSB) has opened green on the ASX after lab tests showed its EmtinB drug could be effective at treating COVID-19.
Go deeper with Google Headlines on:
Reducing amyloid protein
Go deeper with Bing News on:
- Cardiac Amyloidosis: An Approach to Diagnosis and Managementon August 19, 2021 at 5:00 pm
Previously known as primary amyloidosis, systemic amyloid light chain (AL) amyloidosis is the most common form of systemic amyloidosis in developed countries. Although occasionally localized and ...
- Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern Eraon August 17, 2021 at 1:01 pm
Muhamed Baljevic, MD, considers the role of autologous stem cell transplantation for light chain amyloidosis in a peer perspective accompanying an article by Iuliana Vaxman, MD, and Angela Dispenzieri ...
- Will Moderna's Interest Boost Gene Editing Stocks?on August 17, 2021 at 5:01 am
Last November, the company began dosing under its phase 1 study is to evaluate its drug NTLA-2001 which is a single-course, potentially curative therapy for transthyretin amyloidosis. A data ...
- Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate ...on August 16, 2021 at 1:02 pm
Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes disease expected to begin in ...
- Will Moderna’s Interest Boost Gene Editing Stocks?on August 16, 2021 at 7:30 am
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from ...